Sanofi plowing as much as $2B into biologics production over next 3 years

Fierce Pharma ------ Following the recent approval of two new biologics, Dupixent and Kevzara, and a pipeline stuffed full of large-molecule drugs, Sanofi will invest as much as $2 billion on its biologics manufacturing network over the next several years. The disclosure came today during a media event, Reuters reports, and was confirmed by a spokesman for the French drugmaker. Philippe Luscan, executive VP of global industrial affairs, said at the event that the company will plow €600 million ($673 million) a year on its biologics production over the next two to three years. “The investments will reinforce our three major hubs in the U.S., Germany and France,” where Sanofi is doing production of biologics like monoclonal antibodies (mAbs), spokesman Nicolas Kressmann said in a telephone interview. The investments will be for capacity expansion and hiring at different sites in those hubs, he said. To learn more click on the picture below to read the article.